HIFU for Prostate Cancer Now Available at Chesapeake Urology

Published On: 01/26/2018

Chesapeake Urology now offering non-invasive HIFU for localized prostate cancer


Chesapeake Urology, the largest urology practice in Maryland and the Mid-Atlantic region, has partnered with HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States. This partnership will bring High Intensity Focused Ultrasound (HIFU) as a treatment option for localized prostate cancer using Sonablate® HIFU to men in the area.

“We are thrilled to offer this innovative treatment for our patients. Chesapeake Urology strives to be a leader in prostate cancer care, and men will now have access to this non-invasive, outpatient treatment.” said Anup Vora, M.D., director of prostate cancer focal and ablative therapy at Chesapeake Urology.

HIFU precisely focuses ultrasound energy to rapidly heat and destroy tissue in the prostate. Due to its accuracy and precision, areas around the prostate are undamaged which greatly reduces the risk of side effects such as urinary incontinence and erectile dysfunction.

Last summer, a Medicare code was issued by the Centers for Medicare and Medicaid Services that may help some patients cover part of the cost of the HIFU procedure. Additional information about reimbursement may be found at https://www.hifuprostateservices.com/reimbursement.

“We are delighted to have partial Medicare coverage for this procedure. This will enable greater opportunity for patients to have this one-time procedure with its limited side effect profile,” said Dr. Anup Vora.

As a one-time, outpatient procedure, HIFU allows patients to return home the same day as their procedure and return to their normal lifestyle within a few days. HIFU may be repeated, if necessary, and can be used to treat patients that have failed radiation therapy. It does not preclude any future treatments including surgery or radiation.

To learn more about HIFU, visit Chesapeake Urology's Prostate Cancer website here.